Ganciclovir to Prevent Reactivation of Cytomegalovirus in Patients With Acute Respiratory Failure and Sepsis

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

500

Participants

Timeline

Start Date

June 29, 2021

Primary Completion Date

October 25, 2024

Study Completion Date

August 31, 2027

Conditions
Acute Respiratory Failure
Interventions
DRUG

IV Ganciclovir

For first 5 days, dosing of intravenous ganciclovir is 10 mg/kg daily, given as 5 mg/kg every 12 hours (adjusted for renal function). After first 5 days (up to 28 days) IV ganciclovir 5 mg/kg QD ( adjusted for renal function). A minimum interval of 6 hours is required between the first and second dose.

Trial Locations (20)

10467

Montefioure Medical Center, The Bronx

15261

University of Pittsburgh Medical Center, Pittsburgh

21218

Johns Hopkins University, Baltimore

27157

Wakeforest University, School of Medicine, Winston-Salem

27708

Duke University, Durham

29425

Medical College of South Carolina, Charleston

37235

Vanderbilt University, Nashville

43210

Ohio State University Medical Center, Columbus

44195

The Cleveland Clinic Foundation, Cleveland

45221

University of Cincinnati, Cincinnati

48202

Henry Ford Hospital, Detroit

53792

University of Wisconsin School of Medicine & Public Health, Madison

63130

Washington University, St Louis

80204

University of Colorado Denver, Denver

84107

Intermountain Medical Center, Murray

98104

Harborview Medical Center, Seattle

98195

University of Washington Medical Center, Seattle

02115

Brigham & Women's Hospital, Boston

48109-5360

University of Michigan, Ann Arbor

05405

University of Vermont College of Medicine, Burlington

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Fred Hutchinson Cancer Center

OTHER